A type of localised scleroderma known as morphea. Credit: Leith C Jones at English Wikipedia.

Emerald Health Pharmaceuticals (EHP) has started patient enrolment for its Phase I clinical trial of EHP-101 for the treatment of patients with multiple sclerosis (MS) and scleroderma.

The randomised, double-blind, placebo-controlled trial is being carried out in Australia.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It will be conducted in two parts: a single-ascending dose phase (Part 1) and a multiple-ascending dose phase (Part 2).

During the first phase of the trial, the company is expected to enrol up to 64 healthy subjects who will receive EHP-101 or placebo in single-ascending oral doses.

A maximum of 40 healthy subjects will be included in the second phase and will be administered EHP-101 or placebo in multiple-ascending daily oral doses, as determined in Part 1.

The trial’s primary endpoints are to evaluate the safety and tolerability of EHP-101.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“We believe our novel, proprietary oral treatment represents a significant advancement in the treatment of patients with multiple sclerosis (MS) and scleroderma.”

Its secondary endpoints include evaluation of the pharmacokinetic profile, food effects, and pharmacodynamic effects of EHP-101, as well as various biomarkers related to EHP-101’s mechanism of action and its potential for efficacy.

Top-line results from the trial are expected to be published next year.

Emerald Health Pharmaceuticals CEO Jim DeMesa said: “Our research and development team has demonstrated the unique mechanism of action of EHP-101 in preclinical studies, indicating the potential to treat deadly diseases which currently have no cure.

“We believe our novel, proprietary oral treatment represents a significant advancement in the treatment of patients with multiple sclerosis (MS) and scleroderma.

“The initiation of human studies is a major accomplishment as we continue to advance cannabinoid science and deliver on another important development milestone. Based on our recent pre-IND meeting with the US FDA, we believe the results from this Phase I study are likely to support Phase II studies in both MS and scleroderma.”

EHP-101 is an investigational oral drug formulation of a synthetic new chemical entity (NCE) derived from cannabidiol (CBD).